Table 2. Frequencies of Short-term Inflammation Control and Durable Disease Control in paediatric uveitis patients treated with mycophenolate mofetil monotherapy, according to types of uveitis.
| Types of uveitis | Durable Disease Control (n/N (%))a | Short-term inflammation Control (n/N (%))b | Sum of two groups (n/N (%)) |
|---|---|---|---|
| JIA anterior uveitis | 15/25 (60.0%) | 6/25 (24.0%) | 21/25 (84%) |
| Idiopathic intermediate uveitis | 4/9 (44.4%) | 2/9 (22.3%) | 6/9 (66.7%) |
| Idiopathic anterior uveitis | 4/8 (50.0%) | 2/8 (25.0%) | 6/8 (75%) |
| Idiopathic panuveitis | 1/5 (20.0%) | 2/5 (40.0%) | 3/5 (60.0%) |
| Idiopathic posterior uveitis | 0/2 (0.0%) | 1/2 (50.0%) | 1/2 (50.0%) |
| Sarcoid anterior uveitis | 0/1 (0.0%) | 0/1 (0.0%) | 0/1 (0.0%) |
| TINU anterior uveitis | 1/1 (100.0%) | 0/1 (0.0%) | 1/1 (100.0%) |
| Sympathetic ophthalmia panuveitis | 0/1 (0.0%) | 0/1 (0.0%) | 0/1 (0.0%) |
Abbreviations: JIA, juvenile idiopathic arthritis; TINU, tubulointerstitial nephritis and uveitis syndrome.
Defined as patients whose uveitis remained quiescent for at least 2 years on MMF monotherapy with no more than 2 flare-ups successfully treated with either an increase of the MMF dosage or a short duration (<1 month) of corticosteroids.
Defined as patients whose uveitis remained quiescent for less than 2 years with no more than 1 flare-up successfully treated with either an increase of the MMF dosage or a short duration (<1 month) of corticosteroids, or those who initially achieved inflammation control but had to discontinue MMF because of significant adverse effects.
n/N, no. of patients who met the criteria/no. patients with the type of uveitis.